New combo aims to control blood cancer without lifelong treatment
NCT ID NCT05057494
First seen Nov 17, 2025 · Last updated May 13, 2026 · Updated 23 times
Summary
This study tests whether a combination of acalabrutinib and venetoclax can control chronic lymphocytic leukemia or small lymphocytic lymphoma as well as the standard venetoclax plus obinutuzumab regimen. About 607 adults who have not yet been treated for their disease will receive one of the two drug pairs. The goal is to see if the new combo leads to similar or better progression-free survival with a finite treatment duration.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Tucson, Arizona, 85710, United States
-
Research Site
La Jolla, California, 92093-0052, United States
-
Research Site
Longmont, Colorado, 80501, United States
-
Research Site
Jacksonville, Florida, 32256, United States
-
Research Site
Boston, Massachusetts, 02115, United States
-
Research Site
St Louis, Missouri, 63110, United States
-
Research Site
Buffalo, New York, 14263, United States
-
Research Site
New Hyde Park, New York, 11040, United States
-
Research Site
New York, New York, 10065, United States
-
Research Site
Rochester, New York, 14642, United States
-
Research Site
Charlotte, North Carolina, 28204, United States
-
Research Site
Cleveland, Ohio, 44195, United States
-
Research Site
Eugene, Oregon, 97401, United States
-
Research Site
Philadelphia, Pennsylvania, 19104, United States
-
Research Site
Nashville, Tennessee, 37203, United States
-
Research Site
Salt Lake City, Utah, 84112, United States
-
Research Site
Charlottesville, Virginia, 22908, United States
-
Research Site
Seattle, Washington, 98104, United States
-
Research Site
Seattle, Washington, 98109, United States
-
Research Site
Clayton, 3168, Australia
-
Research Site
Geelong, 3220, Australia
-
Research Site
Nedlands, 6009, Australia
-
Research Site
Waratah, 2298, Australia
-
Research Site
Hradec Králové, 500 05, Czechia
-
Research Site
Ostrava - Poruba, 708 52, Czechia
-
Research Site
Pilsen, 30460, CZ, Czechia
-
Research Site
Montpellier, 34295, France
-
Research Site
Tours, 37044, France
-
Research Site
Budapest, 1097, Hungary
-
Research Site
Debrecen, 4032, Hungary
-
Research Site
Bydgoszcz, 85-168, Poland
-
Research Site
Gdansk, 80-219, Poland
-
Research Site
Katowice, 40-519, Poland
-
Research Site
Krakow, 30-727, Poland
-
Research Site
Lódz, 93-513, Poland
-
Research Site
Lublin, 20-090, Poland
-
Research Site
Barcelona, 08025, Spain
-
Research Site
Palma de Mallorca, 07010, Spain
Conditions
Explore the condition pages connected to this study.